Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer
Melissa Khaw(University of Minnesota), Jeffrey S. Miller(Science Museum of Minnesota), Margaret L. MacMillan(University of Minnesota Medical Center), Nicholas A. Zorko(University of Minnesota Medical Center), Carly Selleck(University of Minnesota), Melissa A. Geller(University of Minnesota), Qiping Lu(Beijing University of Civil Engineering and Architecture), Yvette Soignier(University of Minnesota System), Naomi Fujioka(University of Minnesota), Martin Felices(University of Minnesota), Mihir Shetty(University of Minnesota), Peter Hinderlie(University of Minnesota), Zachary Davis(University of Minnesota), Eng Hock Lee(University of Minnesota), Paolo P. Provenzano(University of Minnesota), Philippa R Kennedy(University of Minnesota), Laura E. Bendzick(University of Minnesota), Elise L. Femino(University of Minnesota), Riley C Lyons(University of Minnesota), Shee Kwan Phung(University of Minnesota), Laura E. Kotz(University of Minnesota), John E. Wagner(Kings County Hospital Center), James Lim(XCell Science (United States)), Terran D Stenger(University of Minnesota), Madison Shackelford(University of Minnesota System), Joshua T. Walker(University of Minnesota System)
Cited by 8
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
|Journal of Clinical Oncology|2008|202
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195